Methods of inhibiting kinases
OwnerChristopher Burns, Andrew Wilksinventors
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of inhibiting JAK involving the use of a group of compounds based either upon a 2-amino-6-carba-disubstituted pyrazine scaffold or a 2-amino-6-carba-disubstituted pyridine scaffold. The invention also provides methods of treating JAK-associated disease states.
Claims25
1-34. (canceled)
A method of inhibiting JAK in a cell, which comprises administering to the cell an effective amount of a composition comprising a carrier and a compound of the general formula II:
- or pharmaceutically acceptable salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein
- R6 is C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C2-10 alkylaryl, aryl, or heterocycle, or R6 with N may form a substituted or unsubstituted heterocycle, wherein the alkyl, alkenyl, alkynyl, alkylaryl, aryl, and heterocycle, is optionally substituted with one to three members selected from the group consisting of halo, amino, hydroxy, hydroxyalkyl, alkylamide, arylamide, hydroxyalkylamide, nitrilo, aminoalkylamide, nitriloaryl, alkoxy (in particular methoxy), heterocyclic alkyl wherein heterocycle is a 5-7 membered ring and wherein the hetero atom is O, N or S;
- R7 is C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C2-10 alkylaryl, aryl, halo, OH, or heterocycle, wherein the alkyl, alkenyl, alkynyl, alkylaryl, aryl, and heterocycle, is optionally substituted with one to three members selected from the group consisting of halo, amino, hydroxy, hydroxyalkyl, alkylamide, arylamide, hydroxyalkylamide, nitrilo, aminoalkylamide, nitriloaryl, alkoxy (in particular methoxy), heterocyclic alkyl wherein heterocycle is a 5-7 member ring and wherein the hetero atom is O, N or S.
A method of treating an individual suffering from a JAK-associated disease state, which comprises administering to the individual a composition comprising a pharmaceutically acceptable carrier and a compound of the general formula:
- or pharmaceutically acceptable salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein
- R6 is C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C2-10 alkylaryl, aryl, or heterocycle, or R6 with N may form a substituted or unsubstituted heterocycle, wherein the alkyl, alkenyl, alkynyl, alkylaryl, aryl, and heterocycle, is optionally substituted with one to three members selected from the group consisting of halo, amino, hydroxy, hydroxyalkyl, alkylamide, arylamide, hydroxyalkylamide, nitrilo, aminoalkylamide, nitriloaryl, alkoxy (in particular methoxy), heterocyclic alkyl wherein heterocycle is a 5-7 membered ring and wherein the hetero atom is O, N or S;
- R7 is C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C2-10 alkylaryl, aryl, halo, OH, or heterocycle, wherein the alkyl, alkenyl, alkynyl, alkylaryl, aryl, and heterocycle, is optionally substituted with one to three members selected from the group consisting of halo, amino, hydroxy, hydroxyalkyl, alkylamide, arylamide, hydroxyalkylamide, nitrilo, aminoalkylamide, nitriloaryl, alkoxy (in particular methoxy), heterocyclic alkyl wherein heterocycle is a 5-7 membered ring and wherein the hetero atom is O, N or S.
58-80. (canceled)
Dependencies are inferred from the claim text.